LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

EuropaBio conclusions on Patient BioForum 2025

18/06/2025

POSITION PAPER

Brussels, 18 June 2025

The 2025 edition of the Patient BioForum ‘From Discovery to Access: Towards a Patient-Centric Health European Ecosystem’, was co-hosted by MEP Andras Kulja in the European Parliament on May 13th. The panel was composed of representatives from patient organisations, health biotech industry and the European Commission. Opening the event, MEP Andras Kulja and MEP Stine Bosse delivered keynote speeches placing European patients at the heart of their discourse.

This edition aimed to assess the progress made by the EU in health policies in the previous mandate, while also exploring opportunities in the current mandate to enhance patients’ access to medicines and supporting innovation.

 

Download the full conclusions below

 

EuropaBio conclusions on Patient BioForum 2025

Download
Share
Francesca Degli Agostini
Francesca Degli Agostini

Related posts

11/07/2025

Industrial Decarbonisation Accelerator Act – EuropaBio Position

Read more
07/07/2025

EuropaBio Position on the Critical Medicines Act

Read more
03/07/2025

Life Sciences Strategy Embraces Biotech for Global Impact

Read more

Important links

  • Industrial Decarbonisation Accelerator Act – EuropaBio Position
  • EuropaBio Position on the Critical Medicines Act

Categories in our Newsroom

EBIO-white
EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.
Contact us
Extra links
Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom
Become a member
Media pack
© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.